Sarcopenia and sarcopenic obesity in cardiovascular disease: a comprehensive review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and management without systematic search methods or primary data
PubMed 40759432 · doi:10.4103/singaporemedj.SMJ-2024-233
What was done
This narrative review synthesized current literature on the bidirectional pathophysiological relationship between sarcopenia, sarcopenic obesity, and cardiovascular disease (CVD), covering diagnostic strategies, therapeutic interventions, and remaining research gaps.
What was found
The abstract reports no numerical data or effect sizes. It details a bidirectional relationship wherein sarcopenia promotes adiposity, insulin resistance, and systemic inflammation that increase cardiovascular risk, while cardiac disease and reduced activity accelerate muscle loss. Sarcopenic obesity is characterized as carrying worse prognosis and higher mortality than sarcopenia or obesity alone.
Why it matters
It emphasizes sarcopenia and sarcopenic obesity as key modifiable prognostic factors in cardiac populations, pointing to the need for routine early screening and targeted physical or metabolic management.
Limits
The work is a narrative review without original human subject data, systematic review methodology, or quantitative pooling. The abstract lacks specifics on diagnostic thresholds, sample populations, and intervention outcomes.
Cited by
- supports Having excess glucose or insulin circulating for too long causes inflammation, which is related to sarcopenia, and all of these lead to cardiovascular disease.